Posted this chart in October - been waiting for 0.75p entry price since then - come much quicker than I expected - bought in at .7475p this morning.
Great company prospects and the placing has done what it always does and presented a cheaper buying opportunity. The dilution is about 3.7% but the company has dropped nearly 20% on the news - silly silly market.
Thanks HPC for your tip on this share - much appreciated.
Just seen you message, you tell me about your investment skills i have no idea... lol.
I notice you only post on FRR recently.
I can only see the ones we held in common are ECHO, IRG, AST, CERP , you still got them .
I hold many different ones.
This board has been quiet so I don't check in too often.
This is the first AIM share I dipped into, even before VOG!
I have held since 2009, topped up once and nearly sold once. Fortunately I have a .34 average so am not too unhappy.
Kalan, one of the things that really appealed to me was the SKIL platform, I was envisaging a flow of potential drug candidates. The company have, I understand, dropped everything to concentrate on 3 compounds, all with chances of major success.
The investors whom seem to have done really well out of this are those who trade the swings successfully. Possibly split a holding in two and trade one half and leave the other to ride.
Hi HPC - thanks for your SAR tip - had a quick look this morning and will do some more in depth looking later. Adding it to my watchlist.
This looks like an excellent company with good structures, who are doing a lot of good . They could grow into a much larger company since they have proved up their systems for getting drugs through the pipeline to production and appear to be able to do this profitably - all of this is a great achievement and the company deserves great success commensurate with their achievements.
The rest of this is now with hindsight and so I may sound clever but I am here after the event which is always easier when analysing. In August the company said that the profit was ahead of where the market expected and the sp jumped 10% in a day. it quickly went from .7p up to .85p and I think that was a correct re-rate for the profit we have just seen. After a drop back I think this share got on the radar of 'investors' and moved way ahead to a point where the profits and good news were all in the price. In fact some would have expected much higher profits as the statement that profits were going to be higher than the market expected would have lead me, personally, to expect somewhere between 1 million and 2 million - the £400,000 then comes as a disappointment.
Where next - well the company has lots of work to do to prove up more drugs in the pipeline and the revenues should start to roll from the recent successful drug launch. Where we are with the sp now is in profit taking and it will hit a bargain price at which investors come back and start buying. From a cursory glance I would say that .85p is the correct level and would hope to buy somewhere between .75p and .85p for a bargain price - so that's where I would look to top up if I were you. I can't see a sudden rebound here of any great magnitude unless there is some unexpected news so there is plenty of time IMO - a small bounce may ensue when this drop is over - I would tend to ignore that.
Got it on watch now and may join you here at some time in the next 6 months if the price is right - FDI all over again. We seem to like the same investments HPC - never bought into a drugs company before and I think I need to diversify a little from miners and drillers - thanks again for your tip.
I am an investor in both oxford biomedica and Sareum, although i have no scientific background in the science behind this drug, i believe if the drug trials does what it says on the tin, its future could be massive, i came up on this drug and Saraum whilst researching immunotherapy or immuno-oncology therapies, these new wonder such as CTL019 are in deed wonder drugs that have re-engineered a patient's own blood cells to turbo charge the bodies own immune system to seek out and kill tiny cancer cells in the blood and once injected they can carry on working for decades, however this treatment has only one achilles heel and the is solid tumors if caught early enough before a tumor has formed it can wipe out any and all traces of cancer, however once a tumor has formed and mutated into a solid lump it becomes very difficult for these newly engineered and introduced blood to attack these solid tumors, so i started looking to see if there existed another way of overcoming this problem to create the perfect cancer bomb, so i started looking for drugs and therapies that directly targeted cancer tumors, it was whilst researching this whole area that i stumbled on sareum and their jointly developed oral drug with cancer research UK Checkpoint Kinase 1 (Chk1), I just want to stress again i am no expert, but what i am good at is joining up the dots and seeing things other people might have missed, whilst all the talk on the use of this drug is in combination with chemotherapy, i believe its real promise might well be alongside the latest and most exciting immuno-oncology therapies, targeting the hard to reach solid tumors, as it works by preventing the solid tumors from mutating, dividing or growing i was just wondering if it was possible to take this oral drug for the long term because if it effectively puts the solid tumors growth into a long term sleep or hibernation mode from which it never wake up from when used in combination with any or all immuno-oncology therapies.
Extract from todays RNS
Checkpoint Kinase 1 (Chk1)
Targeting lung, pancreatic and other cancers, licensed to Sierra Oncology
This programme was successfully licensed to Sierra Oncology (NASDAQ:SRRA) in September 2016. The handover of the running of the two ongoing clinical trials was completed in January 2017, resulting in a $2 million milestone payment by Sierra, of which Sareum will receive approximately £450k.
Additional payments in the aggregate amount of up to US$319.5 million become payable upon achievement of certain development, regulatory and commercial milestones. Sierra Oncology will also owe high single to low double digit royalties on the net sales of any product successfully developed. Sareum would be entitled to 27.5% of any such payments.
The Phase I clinical trials in cancer patients initially opened at the Royal Marsden Hospital, London in May 2016 and, since then, two other centres have started to recruit patients; the Velindre Cancer Centre, Cardiff and the Freeman Hospital, Newcastle.
Sierra Oncology has recently announced that it expects to issue an update on these trials towards the end of 2017. It also notes that it is considering further trials of SRA737 in combination with targeted and immuno-oncology therapies, and expects to report preclinical data on these combination studies during the second half of 2017.
At present I am playing with the bookies money. My last sale was on 9 Feb 2011 at 4.45p, which means that my current holding stands me in at 0p!! I have no recollection as to what drove the price 5 years ago but one can only hope the madness occurs again.
It's nice to finally get some cash from all the hard work involved in getting this far and needless to say hopefully all of the lives that can be extended by the treatments in the future.
The company will need another such payment to break even for the year this year based on last financial years' £1.2m loss so there is a way to go yet and 1p values the company at £21m which seems fair value at this stage I'd suggest. There are many hoops to go through to realise the £319m future payments so as ever, GLA that are holding...
I would like to propose a bonus of £50,000 to every shareholder, not in anticipation of anything, but to reward them for sticking with a company which has been loosing value hand over fist for at least 9 years - nice earner for the directors - if they want this company to be private why dont they buy us out. If it is going to earns tons of dosh why is the share price continuing to fall. Surely the directors could put their money into the shares and benefit (suffer) from all this money. No let them award themselves £50000
One of the worst investments I have ever made.
Don't suppose there is anything we can do to stop this?
Before we all get too excited let's remember that there are 1,941,000,000 shares in issue. EPS will need to be very substantial over time to allow for dividends, although substantial royalties might well be in prospect. I haven't looked at the current balance sheet but all the b/f losses would have to be eliminated before divis are allowed to be paid. That is not to say that a share consolidation of say, 1 share for 1000, would not be out of the question. There is the distinct possibility that the 28.75% stake in the future cash flows could attract the attention of managed funds who will pay a DCF calculated amount up front for future long term cash flows. That exit would/could represent a decent exit
I believe this is Thursday pm. Perhaps the analysts will then understand the full potential here and mark up accordingly. In the meantime, yeah usual spike and then drift lower...GLA that are holding. I've got a million shares so a fairly sizeable holding...suddenly!!!
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.